Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04033302

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

Sponsor: Shenzhen Geno-Immune Medical Institute

Conditions Acute Myeloid Leukemia NK Cell Lymphoma T-cell Acute Lymphoblastic Leukemia T-cell Acute Lymphoblastic Lymphoma

Interventions CD7-specific CAR gene-engineered T cells

Updated 6 times since 2019 Last updated: Sep 18, 2019 Started: Sep 1, 2019 Primary completion: Jul 31, 2021 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia and NK Cell Lymphoma and is currently ongoing. Shenzhen Geno-Immune Medical Institute leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Oct 2019 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Aug 2019 — Oct 2019 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shenzhen Geno-Immune Medical Institute

Data source: Shenzhen Geno-Immune Medical Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China